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1. Introduction 
Duocarmycin SA 1 (Scheme 1) is a natural product of the 
cyclopropapyrroloindole (CPI) class with exquisitely potent cyto-
toxicity, having IC50 = 10 pM in L1210 cells.
1
 It acts by binding 
in the minor groove of DNA, with consequent alkylation by the 
strained spirocyclopropane ring. In the structure of the related 
natural product CPI 2 (CC1065), the side-chain, which binds 
non-covalently in the minor groove of DNA prior to covalent 
reaction, is extended to interact over a longer section of the 
groove. This also provides high cytotoxic potency for this comp-
ound (IC50 = 24 pM in L1210 cells).
2
 The semisynthetic experim-
ental drug adozelesin 3 carries the same CPI war-head as does 2 
but the side-chain is simplified; the binding of this molecule into 
the minor groove as a -stacked dimer has been studied in depth.
3
 
The non-covalently-binding units can also be displayed on each 
side of the CPI, as in yatakemycin 4,
4,5
 increasing potency yet 
further (IC50 = 5 pM in L1210 cells). However, this extreme cyto-
toxicity is not selective for tumour cells; compounds such as 2 
also cause a delayed lethality in mice and rabbits.
6,7
  
This lack of selectivity has led to research on the development 
of prodrugs designed to release the potent cytotoxins selectively 
in tumour tissue. Many of these prodrugs release the cyclopropa-
benzaindole (CBI) alkylating warhead, rather than CPI; these 
alkylating units have similar potency but improved stability and 
synthetic accessibility.
8,9
 Tietze has disclosed a prodrug 5, in 
which the exocyclic OH of the seco compound is masked as a -
D-galactoside.
10,11
 This prodrug is essentially non-toxic until the 
-D-galactoside is cleaved by a -D-galactosidase in the context 
of ADEPT; Winstein cyclisation then gives the active CBI. The 
exocyclic oxygen is masked as a cyclic hydroxamate ester in 6; 
bioreductive cleavage of the N–O bond exposes the phenol, trig-
gering the required Winstein cyclisation.
12
 Bioreduction of the 
nitro group to amino in hypoxic tumour cells is also required for 
activation of the nitro-prodrug 7.
13
 The amine then promotes 
Winstein cyclisation, with a sulfonate as the leaving group; 7 
shows ~1000-fold selectivity for killing hypoxic HT29 human 
colon cancer cells vs. oxic HT29 cells in vitro. Oxidative activat-
ion is required for seco-CPI prodrugs such as 8, developed by the 
Bradford group.
14
 Metabolic oxidation, by CYP1A1 or CYP2W1 
(over-expressed in some tumours) gives 9, from which Winstein 
cyclisation leads to the active cytotoxin 10 (Scheme 1). 
Many of these prodrugs are activated by reduction or oxidat-
ion, with only 5 requiring enzyme-catalysed hydrolysis. As part 
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of our studies towards prodrugs where seco-CBIs are released by 
tumour-specific peptidases, we sought an appropriate seco-CBI 
carrying an amine at the 5-position for linkage to the peptide 
through an amide bond.  
2. Results & discussion 
2.1. Design of a protected seco-CBI 
Figure 1 shows our general design of target 5-amino-seco-
CBIs for later linkage to masking peptides. 5-Hydroxy-seco-CBIs 
would be inappropriate, as the link to the peptides would have to 
be aryl esters, which may be chemically labile in biofluids. 
Figure 1 shows the general design of the target 5-amino-seco-
CBIs as structure 11. In this structure, X represents a suitable 
leaving group (tuned to provide a balance of reactivity and stabil-
ity), R represents a suitable acid-labile protecting group (or H), 
R’ represents substitution on the indole side-chain. This substitut-
ion may be the OH or OMe groups found in natural CPIs (con-
tributing to non-covalent binding in the minor groove), additional 
indole or benzofuran units (also contributing to binding) or 
water-solubilising entities. Structure 12 is the specific target for 
the present work. Here, the leaving group X is simply a chloride 
(as in many seco-CPIs and seco-CBIs) and the side-chain exten-
sion is the water-solubilising dimethylaminoethoxy group used 
by Tietze et al.
10
 in their galactosidase-activated prodrug 5. 
2.2. Chemical synthesis 
The key step in assembling the target seco-CBI-warhead 12 is 
cyclisation of a suitable 1,2,4-trisubstituted naphthalene. Two 
cyclisations were investigated: intramolecular 5-exo reaction of a 
chiral 1-metallo-2-oxiranylmethylaminonaphthalene (to give 
enantiopure material) and radical 5-exo cyclisation of a 1-iodo-2-
allylaminonaphthalene (giving a racemate). 
Both routes required an orthogonally protected 1-iodonaphth-
alene-2,4-diamine. Scheme 2 shows the routes investigated there-
to. Firstly, attempted nitration of 4-aminonaphthalen-1-ol 13 
towards 4-amino-2-nitronaphthalen-1-ol failed, giving only naph-
tho-1,4-quinone 14 by oxidation. Martius Yellow 15 is a conven-
ient starting material, with the correct pattern of functionalities 
on the naphthalene ring, although the nitro groups need to be dis-
criminated. Selective reduction of the 4-nitro group with tin(II) 
Scheme 1. Structures of CPI extreme cytotoxins duocarmycin SA 1, CC1065 2, adozelesin 3 and yatakemycin 4 and of seco-CBI prodrugs 5-7; also metabolic 
oxidation of seco-CPI prodrug 8 by CYP1A1 and CYP2W1, leading to insertion of the phenol in 9 and Winstein cyclisation to the active CPI cytotoxin 10. 
O
N
H
N
MeO2C O
N
OMe
OMe
OMe
H
O
N
N
MeSOC
MeO
OH
H
O
N
H
N
O
N
OH
OMe
H
Me
O
Me2N
O
HO
HO OH
OH
O
ClH
H
N
O
N
H
N
O
O
Me
Cl
N
O
N
H
N
O
N
H
H
N
H
Cl
N
O
N
H
Cl
OH
N
H
Cl
N
O
N
H
Cl
O
N
H
N
O
N
H
Cl
H2NOC
OSO2Bn
OMe
NO2
N
O
Oxidation 
by CYP
Winstein
cyclisation
DNA
1: Duocarmycin SA
Me
O
N
H
N
O
N
H
N
O
O
H
3: Adozelesin
4: Yatakemycin
65
7
8 9 10
Non-covalent minor-
groove-binding unit
N O
NH
OMe
OHN
OH2N
Me
O
N
H
N
O
N
OH
OMe
H
2: CC1065
chloride, in a modification of the literature method,
15
 afforded 16. 
Attempted protection of the aniline under basic conditions gave 
only the carbonate 17, arising from reaction at the more nucleo-
philic phenoxide anion. Under neutral conditions, the amine of 
16 is more nucleophilic towards Boc2O, giving 18 in excellent 
yield. The phenol was readily triflated but the attempted replace-
ment of OTf in 19 with iodine to give 20 failed; this had prev-
iously been successful in the conversion of 23 to 24.
16
 An attempt 
to remove the triflyloxy group reductively (aiming for N-Boc 3-
nitronaphthalene-1-amine) served only to cleave the OS bond to 
regenerate 18. With that avenue closed, attempts were made to 
reduce the nitro group of 18 to the corresponding amine, before 
orthogonal protection and introduction of iodine. Hydrogenolysis 
proceeded well in the presence of Pd but all attempts to isolate 
the very electron-rich naphthalene product failed, giving the N-
Boc naphthoquinoneimine 21. Reduction, followed by trifluoro-
acetylation, gave orthogonally protected 22 in moderate yield but 
no routes could be found to elaborate this towards 29. 
An alternative route was investigated, in which discrimination 
between the nitrogens was achieved by selective protection of the 
diamine 25. As reported previously,
16
 the phenolic OH of 15 was 
triflated to give 23 and SNAr reaction with iodide ion furnished 
24. From here, reduction of the nitro groups also caused loss of 
the iodine, affording naphthalene-1,3-diamine 25. This electron-
rich naphthalene is unstable to autoxidation, so it was protected 
as the diBoc derivative 26. The iodine was restored electrophilic-
ally with electrophilic iodine generated from N-iodosuccinimide 
and toluenesulfonic acid, affording 27. However, all attempts to 
remove one Boc group selectively from 27 failed, with many 
acidic conditions also causing loss of the iodine, through a 
Wheland intermediate which was observed by NMR.
16
 Changing 
the point at which selectivity is achieved to the protection step, 
rather than deprotection, treatment of 25 with trifluoroacetic an-
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Scheme 3. Preparation of side-chain unit 33. Reagents & conditions: i, EtOH, 
HCl, reflux; ii, Me2N(CH2)2Cl.HCl, K2CO3, H2O, CHCl3, reflux; iii, Cs2CO3, 
MeOH, H2O, reflux. 
Figure 2. Structures of non-interconverting atropisomers of 38. Chiral 
centres are indicated by green arrows. The iodine is shown in CPK mode to 
emphasise the steric bulk. 
Figure 1. General structure of target 5-amino-seco-CBIs 11 and structure of 
synthetic target 12. R = H or protecting group; R’ = water-solubilising group 
or extension providing additional non-covalent binding; X = leaving group. 
Scheme 2. Synthetic approaches to the key orthogonally protected 1-iodonaphthalene-2,4-diamine 29 Reagents & conditions: i, KNO3, CF3CO2H, -20C; ii, 
SnCl2, aq. HCl, EtOH, <35C; iii, Boc2O, DMAP, CH2Cl2; iv, Boc2O, THF; v, Tf2O, pyridine, 0C; vi, NaI, DMF, 80C; vii, Pd(OAc)2, Ph3P, HCO2H, 65C; 
viii, H2, Pd/C, MeOH, then exposure to air; ix, K2CO3, Na2S2O4, H2O, CH2Cl2 then (F3CCO)2O, Pr
i
2NEt, CH2Cl2; x, SnCl2, EtOAc; xi, N-iodosuccinimide, 
TsOH, THF; xii, (F3CCO)2O, Pr
i
2NEt, THF. 
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hydride under very mild conditions led to reaction at the less-
sterically-encumbered 3-NH2; subsequent protection of the 1-
NH2 with Boc led to the orthogonally protected diamine 28 in 
modest yield. As for 26→27, 28 was iodinated electrophilically 
to provide the key intermediate 29. 
Scheme 3 shows the preparation of the non-covalently binding 
and water-solubilising indole side-chain. The carboxylic acid of 
30 was protected as the ethyl ester 31 before the corresponding 
phenoxide was alkylated with N-(2-chloroethyl)dimethylamine to 
afford 32. Hydrolysis of the ester with caesium carbonate in 
aqueous methanol gave the required carboxylic acid 33. 
With these building blocks in hand, methods were investigated 
to build the target seco-CBIs. Initial attempts sought to exploit 
the ring-closure developed by Tietze et al.,
17
 in which the protec-
ted iodo-(oxiranylmethylamino)naphthalene 34 is metallated with 
a higher-order lithium cuprate (replacing the iodine); attack of the 
aryl-copper on the oxirane then proceeds with chelation-controll-
led regioselectivity and stereoselectivity to form 35 (Scheme 4). 
The 4-nitrobenzenesulfonate (nosylate) ester 37 of R-glycidol 36 
was formed in the usual way; this leaving group was selected as 
this and similar oxiranylmethyl nosylates react with nucleophiles 
strictly in an SN2 manner,
17
 retaining the configuration at the 
oxirane. The F3CCON‒H is the more acidic in 29 and selective 
alkylation of the corresponding anion with 37 afforded 38 in 
good yield. Interestingly, 38 was formed as a mixture of chromat-
ographically separable diastereomeric atropisomers 38A and 
38B. The bulky iodine twists the N-oxiranylmethyltrifluoroacet-
amide out of the plane of the naphthalene by rotation about the 
naphthalene‒N bond, generating a chiral centre. Interconversion 
of the atropisomers by rotation about this C‒N bond is so sev-
erely impeded that it does not occur at ambient temperature. 
Scheme 4. The ring-closure 34→35 developed by Tietze et al.17 and assembly of target 5-amino-seco-CBIs 47 and 48, via radical ring-closure. Reagents & 
conditions: i, MeLi, CuCN, Et2O, THF, N2, -78C; ii, 4-nitrobenzenesulfonyl chloride, Et3N, toluene; iii, 37, K2CO3, acetone, 50C; iv, Bu
tLi, ZnCl2, THF, 
-78C; v, H2C=CHCH2Br, K2CO3, acetone, 50C; vi, H2C=CHCH2Br, KOBu
t, THF; vii, TEMPO, Bu3SnH, benzene, 60C; viii, NaOH, H2O, THF; ix, 33, DIC, 
DMF, 40C; x, Zn, THF / AcOH / H2O (1 : 3 : 1), 70C; xi, Boc2O, THF, reflux; xii, Zn, THF / AcOH / H2O (3 : 1 : 1), 70C; xiii, MsCl (3 eq.), Et3N, DMF, 
0C, then LiCl; xiv, MsCl (1.4 eq.), Et3N, pyridine, 0C then LiCl; xv, HCl, 1,4-dioxane. 
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Owing to the presence of the conventional R-chiral centre in the 
oxirane, the atropisomers are diastereomeric. 
1
H, 
13
C and 
19
F 
NMR analysis of atropisomer 38A also showed a 3:2 mixture of 
rotamers; this probably reflects restricted rotation of the tertiary 
amide carbonyl‒N bond in the trifluoroacetamide. No similar 
rotamers were evident in the corresponding spectra of 38B, sug-
gesting that one rotamer about the amide bond predominates 
greatly in this diastereoisomer. Figure 2 shows the proposed 
structures of these atropisomers, using structures minimised in 
Sybyl and rendered with Accelrys DS. 
Unfortunately, the metalation / cyclisation reaction developed 
by Tietze et al.
17
 failed to form 39 from a mixture of diastereoiso-
mers of 38 The only isolable product (in high yield) was 40, der-
ived from loss of the F3CCO protection (Scheme 4). We specul-
ate that the failure to cyclise was due to the presence of the 
BocN‒H, which may have quenched the cuprate before it could 
engage in metallation. Nucleophilic 
-
CN may then have cleaved 
the trifluoroacetamide. The NMR spectra of 40 showed the pres-
ence of the diastereomeric atropisomers, which were not separ-
able in this case. Furuyama et al. reported that 4-iodophenol 
(carrying an acidic proton) is readily metallated with Bu
t
4ZnLi2 
and the arylzinc reacts with allyl bromide to give exclusively 4-
allylphenol.
18
 This process also failed to cyclise 38 to 40, giving 
only unreacted 38. The door was closed on this potential route to 
homochiral CBIs carrying NHBoc. 
Therefore, a route was developed in which cyclisation of an 
achiral starting material would give a seco-CBI in racemic form. 
Boger and McKie carried out a 5-exo radical cyclisation of 2-(N-
allyl-BocN)-4-benzyloxy-1-iodonaphthalene with TEMPO and 
Bu3SnH to afford racemic 5-BnO-3-Boc-1-(2,2,6,6-tetramethyl-
piperidin-1-yloxy)methyl)-2,3-dihydrobenzo[e]indol-5-yl)carb-
amate.
19
 Similar cyclisations have been disclosed by Stevenson et 
al.
13
 Alkylation of 29 with allyl bromide in the presence of excess 
K2CO3 (Scheme 4) introduced two allyl groups (forming 41) but 
selectivity for the more acidic N‒H was achieved using one equi-
valent of KOBu
t
 to form the monoanion, leading to 42. As for 38, 
42 formed two separable but non-interconvertible conformers, in 
a 4:1 ratio. Clearly, one of the centres of atropisomerism is the 
naphthalene‒N(allyl)COCF3 bond which is restricted by the adj-
acent iodine but one may only speculate that the other source of 
atropisomerism may be the naphthalene‒NHBoc bond, the 
rotation of which might be impeded by the peri 5-H. Cyclisation 
of the atropisomeric mixture to 43 was achieved in 60% yield 
using TEMPO and Bu3SnH in boiling benzene. Tricycle 43 cont-
ains the three groups protected with completely mutually ortho-
gonal masking groups. Selective basic hydrolysis of the trifluoro-
acetyl protection revealed the secondary amine in 44, to which 
the 5-(2-dimethylaminoethoxy)indole-2-carbonyl side-chain was 
affixed in a carbodiimide coupling, affording 45. The O-(2,2,6,6-
tetramethylpiperidin-1-yl) protection was removed reductively, 
after much optimisation. Reaction of 45 with zinc powder in THF 
/ AcOH / H2O (1 : 3 : 1) gave a mixture of 46-49, in which the N-
Boc had been removed in 46 and 48 and the exposed alcohol had 
been esterified in 48 and 49. Zinc acetate is a known Lewis acid 
catalyst for acetylation of primary alcohols.
20
 The amine 48 was 
reprotected to give 49. Reduction of 45 under less acidic condit-
ions (THF / AcOH / H2O (3 : 1 : 1)) allowed uneventful cleavage 
of the N‒O bond to provide 47 in good yield. It only remained 
for the OH to be converted into the chloride and for the N-Boc to 
be removed. Reaction of 47 with mesyl chloride in DMF in the 
presence of Et3N aimed to form the mesylate, which would be 
displaced by chloride ion from added excess LiCl. These condit-
ions introduced the required chlorine but reaction of the MsCl 
with solvent DMF generated a Vilsmeier reagent, which cleaved 
the N‒Boc and formed the dimethylformamidine in 50. Use of 
stoichiometric MsCl in pyridine obviated this side-reaction to 
generate the required protected seco-CBI 51. Finally the Boc pro-
tection was acidolysed to form 52 as the stable dihydrochloride, 
with the cation being unable to trigger Winstein cyclisation.  
2.3. Biochemical and cell-biological evaluation 
The CBIs act by binding and alkylating in the minor groove of 
DNA. When they do so, they cause an increase in the temperature 
at which the strands of double-stranded DNA separate, the so-
called melting temperature (Tm). Indeed, the CPI CC-1065 2 
causes an increase in Tm of up to 31 deg. C.
2
 Thus, to confirm that 
the seco-CBI 52 did form a DNA-reactive entity (presumably the 
CBI 53 formed by Winstein cyclisation (Scheme 5)) in aqueous 
buffer at pH 7.0 and that the expected 53 did bind and react with 
double-stranded DNA, a DNA-melting study was carried out. 
Firstly, to ensure that the putative electrophile 53 was fully 
formed in the buffer, the dihydrochloride salt of 52 was incub-
ated with double-stranded calf-thymus DNA in phosphate buffer 
at pH 7.0 for 1 h and for 24 h and the increase in melting temper-
ature (Tm) was determined for both incubations. The identical 
values demonstrated that the naphthylamine was present as the 
free base at pH 7.0 and that formation of an electrophilic product 
(putatively 53) was complete within 1 h. Thus the full DNA-
melting study was conducted with an incubation time of 1 h (Fig-
ure 3). Panel A shows the primary changes in UV absorption at 
256 nm with temperature, using nine different molar ratios of 
52/53 to DNA (calculated per base-pair), whereas panel B shows 
the first derivative of these primary curves, allowing the Tm to be 
determined as the temperature at the apex of the derivative curve. 
In panel C, Tm is plotted against the molar ratio of 52/53 per 
DNA base-pair. The data confirm that generation of the electro-
phile (putatively 53) takes place rapidly at pH 7.0 and that it does 
bind to and alkylate double-stranded DNA, giving a maximum 
Tm of 13 deg. C. This maximum is achieved with ca. 0.2 drug 
molecules per base-pair. Of course, 52 and 53 are racemates. It is 
known that only one enantiomer of CBIs binds strongly to DNA, 
the other having a shape which does not match the curve of the 
minor groove. Indeed, (-)-duocarmycin SA 1 alkylates DNA at 
least ten-times more efficiently than does its (+)-enantiomer.
21
 
Thus it may be argued that the appropriate ratio to consider is the 
ca. 0.1 ratio of the correct enantiomer per base-pair. 
The cytotoxicity of 52 (presumably forming 53) towards 
LNCaP human prostate carcinoma cells was measured using the 
MTS assay. This cell line produces Prostate-Specific Antigen 
(PSA) and its proliferation is sensitive to androgens.
22
 An IC50 of 
18 ± 3 nM was observed for the antiproliferative effect on these 
cells. To demonstrate that masking the naphthylamine with a car-
bonyl (in the Boc-protected precursor 51) does diminish the cyto-
toxic potency, a similar assay was conducted for 51. This 
compound indeed proved to be markedly less active, with IC50 = 
218 ± 47 nM. In each case, only one of the enantiomers is likely 
to be potent. 
Scheme 5. Proposed Winstein cyclisation of 52 in aq. buffer (pH 7.0). 
3. Conclusions 
 In this paper, the challenge of assembling a seco-CBI carry-
ing a protected amine at the 5-position has been overcome. The 
key steps were preparation of the orthogonally protected 1-iodo-
naphthalene-2,4-diamine 29, allowing selective allylation at the 
2-trifluoroacetamido group, and radical 5-exo ring-closure of the 
N-allyl compound 42 to the seco-CBI core in 43. This cyclisation 
uses an achiral educt and achiral reagents, leading to racemic 43. 
The biological activities of CBIs (binding in the minor groove of 
double-stranded DNA, cytotoxicity) reside in one enantiomer 
only; the development of a stereoselective radical ring-closure 
will be the subject of a later publication. This route has the bene-
fit that 43 contains three functionalities with completely ortho-
gonal protection; the OH is protected by the O-tetramethylpiper-
idine (removable by reduction), the secondary amine site for 
introduction of the non-covalently bonding side-chain is protec-
ted as the base-labile trifluoroacetamide and the primary aniline 
(later to trigger Winstein cyclisation) is masked by the acid-labile 
Boc group. These benefits were exploited by firstly exposing the 
pyrrolidine nitrogen and attaching the indole side-chain in 45. 
The OH was revealed and converted into the required leaving 
group in 51. The target amino-seco-CBI 52 was generated by 
simple rapid acidolysis of the Boc protection. The mutual ortho-
gonality of the protection in 43 means that this intermediate is 
potentially highly versatile, with opportunities to modify the 
order in which the subsequent steps are carried out, leading to 
access to diverse amino-seco-CBIs and to the potential for attach-
ing the deactivating prodrug linker to the 5-NH2 prior to 
“arming” the seco-CBI warhead by installing the leaving group. 
Confirmation that the amino-seco-CBI system is a useful war-
head for release / delivery by peptide prodrugs was provided by 
allowing 52 to undergo Winstein cyclisation in aqueous buffer at 
pH 7.0 to provide the CBI 53. This was demonstrated to be com-
plete in < 1 h by the equivalence of DNA-binding at 1 h and 24 h 
time-points. DNA-melting studies showed the generated 53 to 
bind to and react with double-stranded DNA in the stoichiometry 
of 0.2 molecules per base-pair (0.1 molecules if only the active 
enantiomer is considered). The delivered CBI is also a highly 
potent cytotoxin towards LNCaP human tumour cells, with IC50 
in the nanomolar range. Further studies optimising the potency of 
this warhead towards the picomolar range of 1-4 by modifying 
the non-covalently-binding side-chain will be published later. 
Thus we have identified 43 as an important core intermediate 
for development of potential warheads of extreme potency for 
selective delivery through peptide prodrug systems. 
4. Experimental section 
4.1. General 
1
H and 
13
C NMR spectra were recorded at 400.04 or 500.13 
MHz for 
1
H NMR and 100.59 or 125.76 MHz for 
13
C NMR using 
CDCl3, containing SiMe4, unless otherwise noted. 
13
C NMR 
spectra were assigned using HSQC and HMBC. MS data were 
obtained using electrospray ionisation using a microTOF instru-
ment (Bruker Daltonics, Bremen, Germany), calibrated using 
sodium formate. Mps were obtained using a hot-stage micro-
scope (Reichert-Jung). Experiments were conducted at ambient 
temperature, unless otherwise noted. Solutions in organic 
solvents were dried with MgSO4. Synthetic methods for 14, 16-
19, 21, 22, 31-33, 37, 38, 40, 41 are reported in the Supplement-
ary Information; syntheses of 23-29 were reported previously.
16 
4.2. 1,1-Dimethylethyl N-(1-iodo-2-(N-(prop-2-enyl)-2,2,2-tri-
fluoroacetamido)naphthalen-4-yl)carbamate (42A & 42B) 
Compound 29 (1.22 g, 2.5 mmol) was stirred with KOBu
t
 
(318 mg, 2.8 mmol) in THF (10 mL) under N2 for 30 min, foll-
owed by addition of 3-bromopropene (973 mg, 8.04 mmol). The 
mixture was stirred for 2 h and heated to 50C for 16 h. Sat. aq. 
NaHCO3 was added. Extraction (EtOAc), drying, evaporation 
and chromatography (petroleum ether → petroleum ether / 
EtOAc 19:1) gave 42A (200 mg, 15%) as a yellow solid: mp 
146-147°C; 
1
H NMR (NOESY)  1.56 (9 H, s, Bu
t
), 3.95 (1 H, 
dd, J = 14.2, 7.4 Hz, propenyl 1-H), 4.84 (1 H, dd, J = 14.2, 6.1 
Hz, propenyl 1-H), 5.12 (1 H, dd, J = 17.0, 1.3 Hz, propenyl 3-
H), 5.21 (1 H, dd, J = 10.1, 1.1 Hz, propenyl 3-H), 5.94 (1 H, m, 
propenyl 2-H), 7.27 (1 H, s, NH), 7.51 (1 H, dd, J = 8.2, 6.9, 1.2 
Hz, 6-H), 7.60 (1 H, dd, J = 8.3, 6.9, 1.3 Hz, 7-H), 7.67 (1 H, d, J 
= 8.3 Hz, 5-H), 8.17 (1 H, d, J = 8.1 Hz, 8-H), 8.27 (1 H, s, 3-H); 
13
C NMR  27.30 (CMe3), 53.30 (propenyl 1-C), 80.76 (CMe3), 
91.92 (1-C), 115.16 (q, J = 288.6 Hz, CF3), 119.84 (3-C), 120.03 
(propenyl 3-C), 121.93 (5-C), 125.63 (6-C), 126.43 (4a-C), 
127.97 (7-C), 129.49 (propenyl 2-C), 131.56 (8-C), 134.31 (4-C), 
135.26 (8a-C), 136.78 (2-C), 151.32 (Boc C=O), 156.35 (q, J = 
36.3 Hz, CF3C=O);
 19
F NMR δ -68.20 (CF3); MS m/z 559.0149 
(M + K) (C20H20F3IN2KO3 requires 559.0107); 543.0371 (M + 
Figure 3. DNA-melting studies on 52/53. Equivalents / molar equivalents 
refer to the number of equivalents of 52/53 per base-pair. Panel A: Graphs of 
absorbance (256 nm) vs. temperature for different molar ratios of 52/53. 
Panel B: First derivative graphs from which the melting temperature (Tm) 
values were measured. Panel C: Graph of Tm vs. molar equivalents of 52/53. 
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Na) (C20H20F3IN2NaO3 requires 543.0368); 538.0828 (M + NH4
+
) 
(C20H24F3IN3O3 requires 538.0809). Further elution gave 42B 
(750 mg, 57%) as a yellow oil: 
1
H NMR (NOESY)  1.55 (9 H, 
s, Bu
t
), 3.82 (1 H, dd, J = 14.5, 7.6 Hz, propenyl 1-H), 4.96 (1 H, 
dd, J = 14.5, 5.6 Hz, propenyl 1-H), 5.18 (1 H, dq, J = 18.0, 1.3 
Hz, propenyl 3-H) 5.22 (1 H, dq, J = 11.0, 1.0 Hz, propenyl 3-H), 
5.95 (1 H, m, propenyl 2-H), 7.01 (1 H, s, NH), 7.61-7.67 (2 H, 
m, 6,7-H), 7.85 (1 H, m, 5-H), 7.93 (1 H, s, 3-H), 8.30 (1 H, m, 
8-H); 
13
C NMR  28.27 (CMe3), 54.00 (propenyl 1-C), 81.56 
(CMe3), 115.89 (q, J = 288.7 Hz, CF3), 118.90 (3-C), 120.59 
(propenyl 3-C), 120.66 (5-C), 127.92 (6-C or 7-C), 128.67 (7-C 
or 6-C), 130.30 (propenyl 3-C), 134.38 (8-C), 134.70 (8a-C), 
135.39 (4-C), 140.14 (2-C), 152.45 (Boc C=O), 156.53 (q, J = 
36.5 Hz, F3CC=O); 
19
F NMR δ -68.55 (s, CF3); MS m/z 559.0154 
(M + K) (C20H20F3IN2KO3 requires 559.0107); 543.0437 (M + 
Na)
+
 (C20H20F3IN2NaO3 requires 543.0368); 521.0516 (M + H)
+
 
(C20H21F3IN2O3 requires 521.0549); 486.9814 [(M - Bu
t
) + Na)]
+
 
(C16H12F3IN2NaO3 requires 486.9742). 
4.3. 1,1-Dimethylethyl N-(1-(2,2,6,6-tetramethylpiperidin-1-
yloxy)methyl)-3-(trifluoroacetyl-2,3-dihydrobenzo[e]indol-5-
yl)carbamate (43) 
TEMPO (35.7 mg, 0.23 mmol) and Bu3SnH (21 mg, 73 mol) 
were stirred with 42 (38.1 mg, 73 mol) in benzene (2.0 mL) at 
60C for 135 min. Additional Bu3SnH (21 mg, 73 mol) was 
added at the 30 min, 60 min and 90 min time-points. Evaporation 
and chromatography (petroleum ether / EtOAc 49:1 → 19:1) 
gave 43 (24.1 mg, 60%) as a yellow solid: mp 160-161°C; IR 
max 3364, 3129, 3266, 1700 cm
-1
; 
1
H NMR (NOESY)  0.90 (3 
H, s, piperidine-Me), 1.00 (3 H, s, piperidine-Me), 1.07 (3 H, s, 
piperidine-Me), 1.20 (3 H, s, piperidine-Me), 1.25, (1 H, m, pip-
eridine 4-H), 1.29 (1 H, m, piperidine 3-H or 5-H), 1.35 (1 H, m, 
piperidine 3-H or 5-H), 1.42 (1 H, m, piperidine 3-H or 5-H), 
1.54 (1 H, m, piperidine 4-H), 1.54 (9 H, s, Bu
t
), 1.66 (1 H, m, 
piperidine 3-H or 5-H), 3.83 (1 H, t, J = 8.8 Hz, NOCH), 3.99 (1 
H, m, 1-H), 4.08 (1 H, dd, J = 8.9, 4.3 Hz, NOCH), 4.30 (1 H, t, J 
= 8.7 Hz, 2-H), 4.61 (1 H, d, J = 10.9 Hz, 2-H), 6.10 (1 H, s, 
NH), 7.47 (1 H, t, J = 7.8 Hz, 7-H), 7.53 (1 H, t, J = 7.6 Hz, 8-H), 
7.81 (1 H, d, J = 8.3 Hz, 9-H), 7.90 (1 H, d, J = 8.4 Hz, 6-H), 
8.79 (1 H, s, 4-H); 
13
C NMR  16.97 (piperidine 4-C), 19.97 
(piperidine-Me), 20.05 (piperidine-Me), 28.30 (CMe3), 32.92 
(piperidine-Me), 32.96 (piperidine-Me), 39.52 (piperidine 3-C or 
5-C), 39.60 (piperidine 5-C or 3-C), 39.86 (1-C), , 52.42 (2-C), 
59.88 (piperidine 2,6-C2), 77.26 (NOCH2), 81.05 (CMe3), 111.17 
(4-C), 116.20 (q, J = 288.1 Hz, CF3), 122.15 (6-C), 123.13 (9b-
C), 124.01 (9-C), 125.36 (7-C), 125.52 (5a-C), 127.06 (8-C), 
129.77 (9a-C), 134.19 (5-C), 139.56 (3a-C), 153.34 (Boc C=O), 
154.28 (q, J = 37.5 Hz, CF3C=O); 
19
F NMR δ -72.21 (s, CF3); 
MS m/z 572.2804 (M + Na)
+
 (C29H38F3N3NaO4 requires 
572.2712), 550.2937 (M + H)
+
 (C29H39F3N3O4 requires 
550.2893), 516.2095 (M – 2-methylpropene + Na)
+
 
(C25H30F3N3NaO requires 516.2086). 
4.4. 1,1-Dimethylethyl N-(1-((2,2,6,6-tetramethylpiperidin-1-
yloxy)methyl)-2,3-dihydrobenzo[e]indol-5-yl)carbamate (44) 
Compound 43 (70.4 mg, 0.13 mmol) in THF (4.0 mL) was 
stirred with aq. NaOH (5.0 M, 4.0 mL) for 105 min. The mixture 
was diluted with water and extracted with EtOAc. Washing 
(brine), drying and evaporation gave 44 (60.7 mg, quant.) as a 
yellow oil: IR max 3376, 1715 cm
-1
; 
1
H NMR (NOESY)  1.06 (3 
H, s, piperidine-Me), 1.14 (6 H, s, 2  piperidine-Me), 1.16 (3 H, 
s, piperidine-Me), 1.16-1.42 (6 H, m, piperidine 3,4,5-H6), 1.54 
(9 H, s, Bu
t
), 3.70-3.75 (2 H, m, 2-H2), 3.80-3.90 (2 H, m, 1-H + 
NOCH), 4.00 (1 H, dd, J = 7.6, 4.2 Hz, NOCH), 6.86 (1 H, s, 
Boc NH), 7.20 (1 H, t, J = 7.5 Hz, 7-H or 8-H), 7.38 (1 H, t, J = 
7.1 Hz, 8-H or 7-H), 7.51 (1 H, s, 4-H), 7.69 (2 H, m, 6,9-H2); 
13
C NMR  17.07 (piperidine 4-C), 20.07 (piperidine-Me), 20.26 
(piperidine-Me), 28.33 (CMe3), 32.93 (piperidine-Me), 33.34 
(piperidine-Me), 39.45 (piperidine 3-C or 5-C), 39.59 (piperidine 
5-C or 3-C), 41.05 (1-C), 51.29 (2-C), 59.63 (piperidine 2-C or 6-
C), 59.72 (piperidine 6-C or 2-C), 76.68-77.32 (NOCH2), 80.54 
(CMe3), 105.52 (4-C), 116.77 (5a,9b-C2), 120.98 (6-C or 9-C), 
121.52 (7-C or 8-C), 123.23 (9-C or 6-C), 126.29 (8-C or 7-C), 
131.41 (9a-C), 133.52 (5-C), 149.40 (3a-C), 153.34 (C=O); MS 
m/z 476.2924 (M + Na)
+
 (C27H39N3NaO3 requires 476.2810), 
454.3107 (M + H)
+
 (C27H40N3O3 requires 454.3070). 
4.5. 1,1-Dimethylethyl N-(3-(5-(2-(dimethylaminoethoxy)-
indole-2-carbonyl)-1-((2,2,6,6-tetramethylpiperidin-1-yloxy)-
methyl)-2,3-dihydrobenzo[e]indol-5-yl)carbamate (45) 
N,N’-Diisopropylcarbodiimide (106 mg, 0.81 mmol) was 
stirred with 33 (101 mg, 0.41 mmol) and HOBt (125 mg, 0.81 
mmol) in dry DMF (10 mL) at 0C under N2 for 1 h. Compound 
44 (203 mg, 0.37 mmol) in dry DMF (10 mL) was added. The 
mixture was allowed to warm slowly to 20C during 16 h and 
was heated at 40C for 2 h. Sat. aq. NaHCO3 was added and the 
mixture was extracted (EtOAc). The extract was washed (water, 
brine). Drying, evaporation and chromatography (EtOAc → 
EtOAc / MeOH / Et3N 900:100:1) gave 45 (163 mg, 64%) as a 
yellow oil: IR max 3447, 1727, 1693 cm
-1
; 
1
H NMR (NOESY)  
0.88 (3 H, s, piperidine-Me), 1.00 (3 H, s, piperidine-Me), 1.04 (3 
H, s, piperidine-Me), 1.17 (3 H, s, piperidine-Me), 1.24-1.50 (6 
H, m, piperidine 3,4,5-H6), 1.54 (9 H, s, Bu
t
), 2.45 (6 H, s, 
NMe2), 2.88 (2 H, t, J = 5.5 Hz, CH2NMe2), 3.87 (1 H, t, J = 8.8 
Hz, NOCH), 4.05 (1 H, m, 1-H), 4.13 (1 H, dd, J = 9.0, 4.8 Hz, 
NOCH), 4.17 (2 H, t, J = 5.6 Hz, OCH2), 4.60 (1 H, t, J = 9.1 Hz, 
2-H), 4.81 (1 H, dd, J = 10.2, 1.2 Hz, 2-H), 6.90 (1 H, s, Boc 
NH), 7.00 (1 H, s, indole 7-H), 7.02 (1 H, dd, J = 8.9, 2.4 Hz, 
indole 6-H), 7.13 (1 H, d, J = 2.1 Hz, indole 3-H), 7.36 (1 H, d, J 
= 8.9 Hz, indole 7-H), 7.42 (1 H, t, J = 7.5 Hz, 7-H), 7.50 (1 H, t, 
J = 7.2 Hz, 8-H), 7.84 (1 H, d, J = 8.2 Hz, 9-H), 7.89 (1 H, d, J = 
8.5 Hz, 6-H), 8.90 (1 H, s, 4-H), 9.52 (1 H, s, indole NH); 
13
C 
NMR  16.94 piperidine 4-C), 20.01 (piperidine-Me), 20.16 
(piperidine-Me), 28.30 (CMe3), 33.02 (piperidine-Me), 33.07 
(piperidine-Me), 39.48 (piperidine 3-C or 5-C), 39.53 (piperidine 
5-C or 3-C), 40.20 (1-C), 45.51 (NMe2), 54.66 (2-C), 58.06 
(OCH2CH2NMe2), 59.77 (piperidine 2-C or 6-C), 59.82 
(piperidine 6-C or 2-C), 66.14 (OCH2), 77.64 (NOCH2), 80.69 
(CMe3), 103.71 (indole 3-C), 105.58 (indole 4-C), 111.95 (4-C), 
112.61 (indole 7-C), 116.79 (indole 6-C), 122.13 (6-C), 122.62 
(9b-C), 123.91 (9-C), 124.47 (7-C), 126.60 (8-C), 128.31 (indole 
3a-C), 130.07 (9a-C), 130.99 (5a-C), 131.26 (indole 7a-C), 
133.71 (5-C), 141.39 (3a-C), 153.50 (indole 5-C + indole C=O), 
160.23 (Boc C=O); MS m/z 706.3970 (M + Na)
+
 (C40H53N5NaO5 
requires 706.3944). 
4.6. 1,1-Dimethylethyl N-(3-(5-(2-dimethylaminoethoxy)-
indole-2-carbonyl)-1-hydroxymethyl-2,3-dihydrobenzo[e]-
indol-5-yl)carbamate (47) 
Water (1.0 mL), Zn dust (934 mg, 14.4 mmol) and AcOH (1.0 
mL) were added sequentially to 45 (123 mg, 0.18 mmol) in THF 
(3.0 mL). The mixture was heated at 70C in a sealed pressure 
tube for 16 h. The cooled mixture was filtered (Celite
®
) and the 
solvents were evaporated. Sat aq. NaHCO3 was added and the 
suspension was extracted (EtOAc). The extract was washed 
(water, brine). Drying, evaporation and chromatography (EtOAc 
→ EtOAc / MeOH / Et3N 900:100:1) gave 47 as an off-white 
solid (69.3 mg, 71%): mp 219-220C; IR max 3567, 3423, 3293, 
1684 cm
-1
; 1H NMR ((CD3)2SO) (NOESY)  1.56 (9 H, s, Bu
t
), 
2.36 (6 H, s, NMe2), 2.79 (2 H, t, J = 5.7 Hz, CH2NMe2), 3.23 (1 
H, m, CHOH), 3.85 (1 H, m, CHOH), 4.02 (1 H, m, 1-H), 4.15 (2 
H, t, J = 5.8 Hz, OCH2CH2), 4.74 (2 H, m, 2-H), 5.11 (1 H, br, 
OH), 6.98 (1 H, dd, J = 8.9, 2.4 Hz, indole 6-H), 7.18 (1 H, d, J = 
1.7 Hz, indole 3-H), 7.24 (1 H, d, J = 2.3 Hz, indole 4-H), 7.46 (1 
H, d, J = 8.8 Hz, indole 7-H), 7.48 (1 H, t, J = 8.2 Hz, 7-H), 7.8 
(1 H, t, J = 7.8 Hz, 8-H), 7.96 (1 H, d, J = 8.3 Hz, 9-H), 8.06 (1 
H, d, J = 8.4 Hz, 6-H), 8.58 (1 H, s, 4-H), 9.29 (1 H, s, Boc NH), 
11.66 (1 H, s, indole NH); 
13
C NMR ((CD3)2SO)  28.16 (CMe3), 
42.81 (1-C), 45.35 (NMe2), 54 (2-C), 57.65 (CH2NMe2), 62.81 
(CH2OH), 65.95 (OCH2CH2), 78.95 (CMe3), 103.31 (indole 4-C), 
105.35 (indole 3-C), 113.13 (indole 7-C), 113.61 (4-C), 115.78 
(indole 6-C), 123.38 (9b-C), 123.65 (9-C), 123.88 (6-C), 124.01 
(7-C), 125.78 (5a-C), 126.62 (indole 2-C), 129.72 (9a-C), 131.08 
(indole 3a-C), 131.66 (indole 7a-C), 134.20 (5-C), 141.01 (3a-C), 
152.90 (indole 5-C), 154.07 (Boc C=O), 160.26 (indole C=O); 
MS m/z 567.2608 (M + Na) (C31H36N4NaO5 requires 
567.258340), 545.2829 (M + H) (C31H37N4O5 requires 545.2764). 
4.7. 1,1-Dimethylethyl N-(1-acetoxymethyl-3-(5-(2-dimethyl-
aminoethoxy)indole-2-carbonyl)-2,3-dihydrobenzo[e]indol-5-
yl)carbamate (49) 
Zn dust (354 mg, 5.4 mmol) was added to 45 (123 mg, 0.18 
mmol) in THF (2.0 mL), AcOH (6.0 mL) and H2O (2.0 mL) in a 
pressure tube. The tube was closed and the mixture was heated 
for 70°C for 2 h. Further activated Zn dust (354 mg, 5.4 mmol) 
was added, the tube was resealed and the mixture was heated at 
70C for 21 h, then cooled to 20C. The mixture was diluted with 
THF and filtered (Celite
®
). Evaporation and chromatography 
(EtOAc → EtOAc / MeOH / Et3N 950:50:1) gave two fractions, 
each comprising two compounds. The first fraction (14.0 mg) 
consisted of 46 (MS m/z 587.2945 (M + H) (C33H39N4O6 requires 
587.2870)) and 47 (MS m/z 487.2432 (M + H) (C28H31N4O4 
requires 487.2345)), whilst the second fraction (41.3 mg) consis-
ted of 48 (MS m/ z 445.2328 (M + H) (C26H29N4O3 requires 
445.2240)) and 49 (MS m/z 545.2815 (M + H) (C31H37N4O5 
requires 545.2764)). The first fraction (46 + 47) was boiled under 
reflux with Boc2O (63 mg, 0.29 mmol) in dry THF (10 mL) 
under N2 for 16 h. Evaporation and chromatography (EtOAc → 
EtOAc / MeOH / Et3N 900:100:1) gave 49 as a pale buff solid 
(14.5 mg, 14%): mp 170-171°C; 
1
H NMR (CD3OD) (NOESY)  
1.61 (9 H, s, Bu
t
), 2.03 (3 H, s, COMe), 2.46 (6 H, s, NMe2), 2.88 
(2 H, t, J = 5.4 Hz, CH2NMe2), 4.10 (1 H, dd, J = 10.8, 8.0 Hz, 
CHOAc), 4.19 (2 H, t, J = 5.4 Hz, OCH2CH2NMe2), 4.19 (1 H, 
m, 1-H), 4.59 (1 H, dd, J = 10.8, 3.6 Hz, CHOAc), 4.68 (2 H, d, J 
= 4.4 Hz, 2-H), 7.04 (1 H, dd, J = 9.0, 2.4 Hz, indole 6-H), 7.11 
(1 H, s, indole 3-H), 7.23 ( 1 H, d, J = 2.1 Hz, 4-H), 7.45 (1 H, d, 
J = 8.9 Hz, indole 7-H), 7.51 (1 H, ddd , J = 8.2, 6.8, 1.0 Hz, 7-
H), 7.60 (1 H, ddd, J = 8.0, 6.8, 1.0 Hz, 8-H), 8.01 (1 H. d, J = 
8.3 Hz, 9-H), 8.08 (1 H, d, J = 8.5 Hz, 6-H); 
13
C NMR (CD3OD) 
 20.73 (COMe), 28.78 (CMe3), 41.13 (1-C), 45.82 (NMe2), 
56.45 (2-C), 59.27 (CH2NMe2), 66.48 (CH2OAc), 67.12 
(OCH2CH2NMe2), 81.30 (CMe3), 104.65 (indole 4-C), 107.35 
(indole 3-C), 114.01 (indole 7-C), 115.05 (4-C), 117.67 (indole 
6-C), 123.93 (9b-C), 124.64 (6-C, or 9-C), 124.71 (9-C or 6-C), 
125.87 (7-C), 127.90 (5a-C), 128.21 (8-C), 129.37 (indole 3a-C), 
131.54 (9a-C), 132.06 (indole 2-C), 133.70 (indole 7a-C), 135.96 
(indole 5-C), 142.52 (indole 3a-C), 154.91 (indole 5-C), 156.70 
(Boc C=O), 162.89 (indole C=O), 172.77 (OAc C=O); MS m/z 
587.2945 (M + H) (C33H39N4O6 requires 587.2870). 
4.8. 1-Chloromethyl-3-(5-(2-dimethylaminoethoxy)indole-2-
carbonyl)-5-(N,N-dimethylformamidino)-2,3-dihydrobenzo-
[e]indole (50) 
Et3N (28 mg, 0.27 mmol) was added to 47 (30 mg, 54 μmol) 
in dry DMF (0.4 mL) under N2 at 0°C, followed by MsCl (19 mg, 
0.16 mmol). The mixture was stirred at 0°C for 1 h. LiCl (134 
mg, 3.2 mmol) was added and the mixture was stirred at 20C for 
3 d. Water (5 mL) was added and the solvents were evaporated 
(< 30°C). Chromatography (EtOAc → EtOAc / MeOH / Et3N 
950:50:1) gave 50 (21 mg, 76%) as a yellow solid: mp 229-
230°C; 
1
H NMR (NOESY)  2.42 (6 H, s, CH2NMe2), 2.84 (2 H, 
t, J = 5.6 Hz, CH2NMe2), 3.04 (3 H, br, formamidine-Me), 3.10 
(3 H, br, formamidine-Me), 3.45 (1 H, t, J = 10.9 Hz, CHCl), 
3.98 (1 H, dd, J = 11.4, 3.1 Hz, CHCl), 4.14 (1 H, m, 1-H), 4.16 
(2 H, t, J = 5.6 Hz, OCH2), 4.63 (1 H, t, J = 8.6 Hz, 2-H), 4.78 (1 
H, dd, J = 9.3, 1.5 Hz, 2-H), 7.00 (1 H, d, J = 8.8 Hz, indole 6-
H), 7.02 (1 H, d, J = 2.3 Hz, indole 3-H), 7.14 (1 H, d, J = 2.2 
Hz, indole 4-H), 7.35 (1 H, d, J = 8.9 Hz, indole 7-H), 7.38 (1 H, 
t, J = 7.3 Hz, 7-H), 7.50 (1 H, dd, J = 8.0, 1.1 Hz, 8-H), 7.67-7.69 
(2 H, m, 9-H + formamidine-H), 7.70 (1 H, s, 4-H), 8.47 (1 H, d, 
J = 8.3 Hz, 6-H), 9.59 (1 H, s, indole NH); 
13
C NMR  35 (br, 
formamidine-Me), 40 (br, formamidine-Me), 43.30 (1-C), 45.63 
(CH2NMe2), 46.08 (CH2Cl), 55.05 (2-C), 58.21 (OCH2CH2N), 
66.30 (OCH2), 103.70 (indole 4-C), 104.68 (4-C), 105.97 (indole 
3-C), 112.63 (indole 7-C), 117.10 (indole 6-C), 118.26 (9b-C), 
121.97 (9-C), 123.64 (7-C), 125.76 (6-C), 127.26 (8-C), 127.81 
(5a-C), 128.25 (indole 3a-C), 129.75 (9a-C), 130.81 (indole 7-C), 
131.36 (indole 7a-C), 142.03 (3a-C), 150.91 (5-C), 153.03 (form-
amidine CH), 153.66 (indole 5-C), 160.49 (indole C=O); MS m/z 
520.2375 (M + H)
+
 (C29H32
37
ClN5O2 requires 520.2293), 
518.2341 (M + H)
+
 (C29H32
35
ClN5O2 requires 518.2323). 
4.9. 1,1-Dimethylethyl N-(1-chloromethyl-3-(5-(2-dimethyl-
aminoethoxy)indole-2-carbonyl)-2,3-dihydrobenzo[e]indol-5-
yl)carbamate (51) 
MsCl (7.0 mg, 61 mol) was stirred with 47 (24 mg, 44 μmol) 
in dry pyridine (0.7 mL) under N2 at 0°C for 1 h. LiCl (92 mg, 
2.2 mmol) was added and the mixture was stirred at 20C for 7 d. 
EtOAc was added, followed by sat. aq. NaHCO3. The mixture 
was extracted with EtOAc. The extract was washed (water, 
brine). Drying, evaporation and chromatography (EtOAc → 
EtOAc / MeOH / Et3N 980:20:1) gave 51 (16.3 mg, 66%) as a 
yellow solid: mp >250°C; 
1
H NMR (COSY / NOESY)  1.55 (9 
H, s, Bu
t
), 2.37 (6 H, s, NMe2), 3.47 (1 H, t, J = 10.7 Hz, ClCH), 
3.96 (1 H, dd, J = 11.2, 2.9 Hz, ClCH), 4.13 (2 H, t, J = 5.8 Hz, 
OCH2), 4.14 (1 H, m, 1-H), 4.66 (1 H, t, J = 8.6 Hz, 2-H), 4.82 (1 
H, dd, J = 9.0, 1.7 Hz, 2-H), 6.91 (1 H, s, Boc NH), 7.01 (1 H, d, 
J = 1.4 Hz, indole 3-H), 7.04 (1 H, dd, J = 8.9, 2.4 Hz, indole 6-
H), 7.14 (1 H, d, J = 2.2 Hz, indole 4-H), 7.35 (1 H, d, J = 8.9 
Hz, indole 7-H), 7.45 (1 H, ddd, J = 8.3, 7.0, 1.1 Hz, 7-H), 7.55 
(1 H, ddd, J = 7.9, 6.8, 0.9 Hz, 8-H), 7.77 (1 H, d, J = 8.2 Hz, 9-
H), 7.90 (1 H, d, J = 8.4 Hz, 6-H), 8.92 (1 H, s, 4-H), 9.42 (1 H, 
s, indole NH); 
13
C NMR  28.28 (CMe3), 43.40 (1-C), 45.84 
(NMe2 + CH2Cl), 54.94 (2-C), 58.37 (CH2NMe2), 66.59 (OCH2), 
80.92 (CMe3), 103.64 (indole 4-C), 105.90 (indole 3-C), 111.46 
(4-C), 112.59 (indole 7-C), 117.32 (indole 6-C), 120.77 (9b-C), 
122.37 (6-C), 123.04 (9-C), 124.71 (5a,7-C2), 127.23 (8-C), 
128.24 (indole 3a-C), 129.68 (9a-C), 130.49 (indole 2-C), 131.32 
(indole 7a-C), 134.75 (5-C), 141.66 (3a-C), 153.28 (Boc C=O), 
153.86 (indole 5-C), 160.41 (indole C=O); MS m/z 565.2382 (M 
+ H)
+
 (C31H36
37
ClN4O4 requires 565.2396), 563.2443 (M + H)
+
 
(C31H36
37
ClN4O4 requires 563.2425), 427.2157 ((M – (Boc + Cl) 
+ H)
+
 (C26H27N4O2 requires 427.2134). 
4.10. 1-Chloromethyl-3-(5-(2-dimethylaminoethoxy)indole-2-
carbonyl)-2,3-dihydrobenzo[e]indole-5-amine dihydrochlor-
ide (52) 
Compound 51 (18.6 mg, 33 mol) was stirred with HCl in 
1,4-dioxane (4.0 M, 2.0 mL) for 2 h. The solvent and excess HCl 
were evaporated at 20°C. The residue was triturated with MeCN 
and Et2O. Drying gave 52 (15.3 mg, quant.) as a pale buff solid: 
mp >250°C. A sample in EtOAc was washed (sat. aq. NaHCO3
,
 
brine). Drying and evaporation gave the free base as a yellow 
solid: mp > 250C; 
1
H NMR ((CD3)2SO) (NOESY)  2.90 (6 H, 
s, NMe2), 3.55 (2 H , t, J = 4.2 Hz, CH2NMe2), 3.77 (1 H, dd, J = 
11.0, 8.2 Hz, ClCH), 3.99 (1 H, dd, J = 11.1, 3.1 Hz, ClCH), 4.15 
(1 H, m, 1-H), 4.33 (2 H, t, J = 4.9 Hz, OCH2), 4.52 (1 H, dd, J = 
10.8, 1.5 Hz, 2-H), 4.75 (1 H, t, J = 10.7 Hz, 2-H), 7.00 (1 H, d, J 
= 8.8 Hz, indole 6-H), 7.10 (1 H, d, J = 1.7 Hz, indole 3-H), 7.26 
(1 H, d, J = 1.9 Hz, indole 4-H), 7.32 (1 H, t, J = 7.9 Hz, 7-H), 
7.45 (1 H, d, J = 8.9 Hz, indole 7-H), 7.48 (1 H, t, J = 7.4 Hz, 8-
H), 7.75-7.80 (2 H, m, 4,9-H2), 8.08 (1 H, d, J = 8.5 Hz, 6-H), 
11.66 (1 H, s, indole NH); 
13
C NMR ((CD3)2SO)  41.40 (1-C), 
42.89 (NMe2), 47.51 (ClCH2), 55.04 (2-C), 55.67 (CH2NMe2), 
62.70 (OCH2), 99.50 (4-C), 104.01 (indole 4-C), 105.00 (indole 
3-C), 113.30 (indole 7-C), 115.54 (indole 6-C), 117.55 (9b-C), 
120.67 (4a-C), 122.46 (7-C), 123.05 (9-C), 123.37 (6-C), 126.91 
(8-C), 127.11 (indole 2-C), 130.01 (9a-C), 131.52 (indole 3a-C), 
131.95 (indole 7a-C), 142.78 (5-C), 151.97 (indole 5-C), 157.90 
(3a-C), 158.17 (C=O); MS m/z 465.1910 (M + H) (C26H28
37
Cl-
N4O2 requires 465.1871), 463.1874 (M + H) (C26H28
35
ClN4O2 
requires 463.1901). 
4.21. DNA-melting studies 
The buffer was prepared by dissolving NaH2PO4 (1.17 g, 9.75 
mM), ethylenediaminetetraacetic acid (EDTA) disodium salt 
dihydrate (372 mg, 1.0 mM) and NaCl (438 mg, 7.5 mM) in 18.2 
M MilliQ water (800 mL). The pH was adjusted to pH 7.0 
using aq. NaOH (0.1 M) or aq. HCl (0.1 M) as required and 
Milli-Q water was added to 1.00 L. The calf thymus DNA stock 
solution was prepared by dissolving DNA in 9.75 mM phosphate 
buffer to a concentration of 1.0 mg mL
-1
. The stock was diluted 
with buffer until an absorbance of 0.6 at 256 nm was obtained. 
This gave a concentration of ca. 32 g mL
-1
, using the Beer-
Lambert Law with  = 6600 M
-1
 cm
-1
. Compound 52 (1.04 mg, 
1.94 mol) was dissolved in DMSO (1.00 mL) to make a stock 
solution. Different volumes of this solution were added to the 
DNA solution (3.00 mL) in the appropriate quartz cuvettes and 
the mixtures were incubated at room temperature for 1.0 h to 
allow alkylation of the DNA. Five parallel cuvettes were prep-
ared: A: blank containing buffer and DMSO (40 L); B,C: con-
trols containing DNA, buffer and DMSO (40 L); D,E: tests con-
taining 52/53, DNA, buffer and DMSO. All cuvettes contained 
the same total volume of DMSO (40 L). The absorbance at 256 
nm was monitored for each sample over the range of 40C → 
95C with the temperature rising at a rate of 0.5 deg. C min
-1
, 
using a complete PC-controlled spectrometer system (Perkin 
Elmer Lambda BioDNA Melt system including PTP-6 temper-
ature-controlled programmer for simultaneous curves, UVTemp-
lab software and in-cuvette temperature sensor). Both direct and 
first-derivative graphs were plotted and the Tm was taken as 
temperature at the maximum in the first-derivative plot. 
4.22. Cytotoxicity assays 
The human prostate cancer cell line LNCaP (Sigma-Aldrich) 
was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
with high glucose (4.5 g L
-1
), foetal bovine serum (FBS, 20% 
(v/v)), penicillin (100 U mL
-1
) and streptomycin sulfate (100 μg 
mL
-1
) at 37C in a humidified atmosphere containing 5% CO2 
(v/v). The MTS assay was conducted as described previously.
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